NCI-2017-01360

A PHASE II/III MULTICENTER STUDY EVALUATING THEEFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON?SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (B-FAST BLOOD-FIRST ASSAY SCREENING TRIAL)

This is a Phase II/III multicenter study focused on evaluating the effectiveness and safety of multiple targeted therapies for patients with advanced or metastatic non-small cell lung cancer (NSCLC). The study is specifically targeting patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have actionable somatic mutations detected in blood samples. These mutations are genetic alterations in the cancer cells that can be targeted by specific therapies designed to interfere with the growth and spread of cancer. The trial evaluates multiple targeted therapies. These therapies are tailored to specifically target the identified somatic mutations detected in the blood of the patients enrolled in the study. Targeted therapies aim to disrupt specific molecular pathways involved in cancer growth, potentially leading to more effective treatment outcomes with fewer side effects compared to traditional chemotherapy. The primary goal of this study, known as the B-FAST (Blood-First Assay Screening Trial), is to assess how well these targeted therapies work in treating advanced or metastatic NSCLC with actionable somatic mutations detected in blood samples. The study will also evaluate the safety profiles of these treatments in this patient population.

advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

metastatic: cancer that has spread from its original location or organ to other parts of the body.

non-small cell lung cancer (NSCLC): A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

mutations: an alteration in the genetic material of a cell or a virus that can be inherited by its descendants

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT03178552

Clinical Trial Site: Einstein

To see all available clinical trials click here.